Abdelhakeem A, Wang X, Rogers JE, et al. - By previous reports, patients whose tumor overexpresses Her2 at 3+ level via immunohistochemistry (IHC) fare better compared with those whose tumor overexpresses Her2 at 2+ level (with ERBB2 amplified), and thus, it would be crucial to compare the result of patients whose tumor expresses Her2 at 2+ level but further classify by gene amplification studies as positive or negative, so, researchers analyzed patients suffering from advanced gastroesophageal adenocarcinoma with low Her2 protein expression (2+ by IHC). Their tumors were assessed for gene amplification of ERBB2 using fluorescence in situ hybridization. First-line therapy was received by all patients, and based on Her2 status, trastuzu­mab was added. For the whole cohort, the median overall survival and the median progression-free survival were estimated to be 26 months and 12.2 months, respectively. Findings revealed that similar clinical outcomes were found in patients with Her2 positivity or negativity when tumors showed lower Her2 protein expression (2 + by IHC).